Bispecific Antibody Merging Checkpoint Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current immune checkpoint therapies require multiple molecules to target multiple immune checkpoint proteins, leading to increased risks of severe adverse events and off-target immunological effects.
Innovation Solution
Development of polypeptide molecules comprising immune checkpoint inhibiting polypeptides, such as CTLA-4, PD-1, PD-L1, and B7.1/B7.2, linked with polypeptide linkers, to simultaneously inhibit multiple immune checkpoint proteins with a single molecule.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Adaptability or versatility
If multiple separate immune checkpoint inhibitor molecules are used to target multiple immune checkpoint proteins, then comprehensive immune checkpoint coverage is achieved, but the risk of severe adverse events and off-target immunological effects increases
Solution Approach 1:
The patent combines multiple immune checkpoint inhibitor molecules into a single bispecific T-cell engaging antibody molecule. This single molecule simultaneously targets two different immune checkpoint proteins (such as PD-L1 and B7.1/B7.2), enabling comprehensive immune checkpoint coverage while reducing the number of separate molecules administered and potentially reducing off-target effects associated with multiple separate therapies.
Solution Approach 2:
The bispecific T-cell engaging antibody is designed with multi-functionality, serving as both a PD-L1 inhibitor and a B7.1/B7.2 inhibitor within a single molecular structure. This universal approach allows one molecule to perform multiple immune checkpoint inhibition functions, addressing the need for comprehensive coverage while simplifying the therapeutic regimen and potentially reducing adverse events.
2Adaptability or versatility
If multiple separate immune checkpoint inhibitor molecules are administered, then multiple immune checkpoint proteins can be targeted, but device complexity and treatment protocol complexity increase
Solution Approach 1:
The invention merges the functionality of multiple separate immune checkpoint inhibitors into a single bispecific antibody molecule. This consolidation reduces treatment protocol complexity by requiring administration of one molecule rather than multiple separate molecules, while maintaining the ability to target multiple immune checkpoint proteins simultaneously.
3Object-affected harmful factors
If a single polypeptide molecule is designed to inhibit multiple immune checkpoint proteins, then adverse events may be reduced, but manufacturing complexity and molecular design complexity increase
Solution Approach 1:
The bispecific T-cell engaging antibody combines multiple immune checkpoint inhibitor functionalities into a single polypeptide chain with a defined structural architecture. While the molecular design is complex, the patent provides specific structural frameworks and linker designs that facilitate manufacturing. The single-molecule approach potentially reduces adverse events by providing more controlled and predictable pharmacokinetics and immunogenicity profiles compared to combinations of multiple separate molecules.
Data Source
AI summary
The present application provides for polypeptides comprising immune checkpoint polypeptides, compositions comprising the same, and methods of using the same.